Cited by 155Pancreatic and Hepatic Oncology ResearchChromatin Remodeling and CancerSignaling Pathways in Disease

Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation

Open access
Roy, Nilotpal, Malik, Shivani, Villanueva, Karina E., Urano, Atsushi, Lu, Xinyuan, Von Figura, Guido, Seeley, E. Scott, Dawson, David W. +2 more·2015·Genes & Development

Abstract

Pancreatic ductal adenocarcinoma (PDA) develops predominantly through pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN) precursor lesions. Pancreatic acinar cells are reprogrammed to a “ductal-like” state during PanIN-PDA formation. Here, we demonstrate a parallel mechanism operative in mature duct cells during which functional cells undergo “ductal retrogression” to form IPMN-PDA. We further identify critical antagonistic roles for Brahma-related gene 1 (Brg1), a catalytic subunit of the SWI/SNF complexes, during IPMN-PDA development. In mature duct cells, Brg1 inhibits the dedifferentiation that precedes neoplastic transformation, thus attenuating tumor initiation. In contrast, Brg1 promotes tumorigenesis in full-blown PDA by supporting a mesenchymal-like transcriptional landscape. We further show that JQ1, a drug that is currently being tested in clinical trials for hematological malignancies, impairs PDA tumorigenesis by both mimicking some and inhibiting other Brg1-mediated functions. In summary, our study demonstrates the context-dependent roles of Brg1 and points to potential therapeutic treatment options based on epigenetic regulation in PDA.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/gad.256628.114

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Chromatin regulatory factors may have context-specific and biphasic functions in PDAC, with both tumor suppressor and oncogenic roles at distinct stages of tumorigenesis.

    “chromatin regulatory factors may have a more context-specific and biphasic function in PDAC, with studies in autochthonous models suggesting both tumor suppressor and oncogenic functions during distinct stages of tumorigenesis101,102.”

    From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [101]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Roy, N., Malik, S., Villanueva, K. E., Urano, A., Lu, X., Von Figura, G., Seeley, E. S., Dawson, D. W., Collisson, E. A., & Hebrok, M.
Affiliations
  • University of California, San Francisco (US)
  • University of California, Los Angeles (US)
Corresponding author
Hebrok, Matthias
Venue
Genes & Development
Published
2015-03-15
Volume
29
Issue
6
Pages
658-671
ISSN
  • 0890-9369 (ISSN-L)
  • 1549-5477
OpenAlex
W2112350662
Cited by
155
References
64
Citations by year
2026: 8 · 2025: 5 · 2024: 8 · 2023: 15 · 2022: 9 · 2021: 17 · 2020: 19 · 2019: 20 · 2018: 17 · 2017: 16 · 2016: 15 · 2015: 6
Type
posted content
Language
en
Open access
Licence
cc-by-nc
Locations
  • Genes & Development (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
  • mediaTUM (Technical University of Munich) (submittedVersion)
Funders
  • National Institutes of Health (R01CA172045)
  • National Cancer Institute (R01CA112537)
  • NIH (R01CA178015)
  • NCI (K08CA137153)
  • American Association of Cancer Research
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords
SMARCA4, pancreatic ductal adenocarcinoma, intraductal papillary mucinous neoplasm, pancreatic intraepithelial neoplasia, SWI/SNF complex, dedifferentiation, tumor initiation, JQ1, epigenetic regulation, tumor suppressor, oncogenic transformation
MeSH terms
Animals, Azepines, Cell Transformation, Neoplastic, DNA Helicases, Humans, Nuclear Proteins, Pancreatic Neoplasms, Transcription Factors, Triazoles, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins p21(ras), Carcinoma, Pancreatic Ductal, Mice, SOX9 Transcription Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review